Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing *Pseudomonas aeruginosa* isolate in Canada

Shadi Sepehri PhD¹, Guillaume Poliquin MD^{1,2,3}, Nora Alfattoh MD², David Boyd MSc³, Michael Mulvey PhD^{1,3}, Andrew Denisuk BSc¹, Sergio Fanella MD^{1,2}, James Karlowsky PhD^{1,4}, Andrew Walkty MD^{1,4}

S Sepehri, G Poliquin, N Alfattoh, et al. Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing *Pseudomonas aeruginosa* isolate in Canada. Can J Infect Dis Med Microbiol 2014;25(4):229-231.

A case of osteomyelitis in an infant following a burn injury sustained in Pakistan caused by a GES-13-producing *Pseudomonas aeruginosa* (the first reported in Canada) and an OXA-48 producing *Klebsiella pneumoniae* is described. The present case serves to highlight the importance of international travel as a risk factor for infection with carbapenemase-producing bacteria and the challenges in the laboratory detection of these organisms.

Key Words: Carbapenemase; Continuous infusion; GES-13; Multidrug-resistant; OXA-48

CASE PRESENTATION

A four-month-old female infant presented to the emergency department of the Children's Hospital in Winnipeg, Manitoba, with full-thickness burns of the anterior lower limbs. According to the infant's mother, the burns had been sustained two weeks previously while visiting family in Karachi, Pakistan, when an electronic steamer used to relieve the infant's nasal congestion slipped and spilled hot water over her legs. She was taken to an emergency department in Karachi, where she was treated with oral amoxicillin-clavulanate and daily dressing changes. Within one week, her wounds became infected. At this time the family left Pakistan without further intervention in the hope of continuing her treatment in Winnipeg. On the way to Winnipeg, the infant was taken to The Montreal Children's Hospital (Montreal, Quebec). During her <24 h stay, her wounds were evaluated and her antimicrobial therapy was stopped due to diarrhea.

On presentation in Winnipeg, the infant's temperature was 39.1°C, her heart rate was 204 beats/min, her respiratory rate was 36 breaths/min, her blood pressure was 114/64 mmHg and her oxygen saturation was 99% on room air. Examination of her lower limbs revealed 15% body surface area of full-thickness burns, encompassing areas of both legs and feet. The three lateral toes of her right foot were gangrenous. Yellowish discharge was observed from both of her ears. Her medical history was unremarkable. She was born in Canada at 40 weeks' gestation via emergency Caesarean section due to fetal bradycardia. Her vaccinations were up to date.

Initial investigations revealed a white blood cell count of 29×10^9 cells/L (28% neutrophils and 54% lymphocytes), a hemoglobin level of 102 g/L and a platelet count of 189×10^9 cells/L. Blood, urine, ear

Une ostéomyélite causée par de multiples bactéries à Gram négatif productrices de carbapénémases : premier rapport de cas d'un isolat de *Pseudomonas aeruginosa* producteur d'enzymes de type GES-13 au Canada

Les auteurs décrivent un cas d'ostéomyélite chez un nourrisson après une brûlure subie au Pakistan. Cette ostéomyélite était causée par un *Pseudomonas aeruginosa* producteur d'enzyme de type GES-13 (le premier déclaré au Canada) et un *Klebsiella pneumoniae* producteur d'enzyme de type OXA-48. Ce cas fait ressortir l'importance des voyages internationaux comme facteur de risque d'infection par des bactéries productrices de carbapénémases ainsi que la difficulté de déceler ces organismes en laboratoire.

swabs and surveillance swabs for methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci were collected for culture. The patient was taken to the operating room, where her wounds were debrided, the aforementioned gangrenous toes were amputated, and swabs from the left leg and right foot were submitted to the laboratory for microbiological investigations. Antimicrobial therapy was initiated with vancomycin and meropenem. The patient was admitted to the pediatric intensive care unit after her surgery.

Bacteria isolated on culture and their susceptibility patterns are listed in Table 1. Antimicrobial susceptibility testing was performed using the VITEK2 system (bioMérieux, Canada), with minimum inhibitory concentrations (MICs) interpreted using 2013 Clinical and Laboratory Standards Institute (CLSI) breakpoints (1). Colistin MICs were obtained by broth microdilution. Aztreonam and tigecycline MICs were determined by E-test. United States Food and Drug Administration interpretive breakpoints were used for tigecycline. Multidrug resistance was defined as resistance to ≥ 3 antimicrobial classes. Two different strains of MRSA (isolates A and B) were isolated from the nares, as well as the ears, the left leg and the right foot. One isolate was a Canadian MRSA strain type 7 (USA400) according to pulsed-field gel electrophoresis, while the other MRSA had a unique pulsed-field gel electrophoresis pattern that did not match any of the existing Canadian MRSA strain types (2). Multidrug-resistant (MDR) strains of *Klebsiella pneumoniae* (isolate C) and *Pseudomonas aeruginosa* (isolate D) were recovered from wounds on the left leg and right foot (Table 1). The *K pneumoniae* isolate had a relatively elevated meropenem MIC of 1 mg/L, which is at the CLSI defined breakpoint for susceptibility. This prompted a change in meropenem administration from intermittent

¹Department of Medical Microbiology; ²Department of Pediatrics and Child Health, University of Manitoba; ³National Microbiology Laboratory;

⁴Diagnostic Services Manitoba, Winnipeg, Manitoba

Correspondence: Dr Andrew Walkty, MS673B Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9.

Telephone 204-787-1161, fax 204-787-4699, e-mail awalkty@dsm Manitoba.ca

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com

TABLE 1
List of bacteria recovered and their antimicrobial susceptibility patterns

Isolate designation	Isolate					
	A and B	A and B	C	D	E	F
Collection date	December 14, 2012	December 14, 2012	December 14, 2012	December 14, 2012	December 20, 2012	December 20, 2012
Specimen source	Nares swab	Sterile fluid swab	Sterile fluid swab	Sterile fluid swab	Tissue biopsy	Tissue biopsy
Site	Nares	Right foot, left leg, left ear	Right foot, left leg	Right foot, left leg	Right foot first metatarsal	Right foot first metatarsal
Organism	MRSA*	MRSA	<i>Klebsiella pneumoniae</i>	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i>	<i>Providencia stuartii</i>
Susceptibility						
Ampicillin			R			R
Oxacillin	R, R	R, R				
Amoxicillin-clavulanate			R			
Piperacillin-tazobactam			R		R	S
Cefazolin			R			R
Ceftazidime			R	R	R	R
Ceftriaxone			R			R
Ertapenem			R			S
Meropenem			S†	I	R	S
Aztreonam			R	R		
Ciprofloxacin			R	S	R	R
Amikacin			R	R	S	R
Gentamicin			R	R	R	R
Tobramycin			R	R	S	R
Tigecycline			S‡	MIC >8 mg/L		
Erythromycin	S, R	S, R				
Clindamycin	S, R	S, R				
Linezolid	S, S	S, S				
Vancomycin	S, S	S, S				
Trimethoprim-sulfamethoxazole	R, R	R, R	R			R
Colistin			MIC 0.5 mg/L	S	S	

All susceptibilities are based on Clinical and Laboratory Standards Institute M100-S23 interpretive breakpoints (1). Minimum inhibitory concentrations (MICs) are reported when no Clinical and Laboratory Standards Institute interpretive breakpoints exist. *Two strains of methicillin-resistant *Staphylococcus aureus* (MRSA) were isolated from the patient's nares; the same two strains were also isolated from the right foot, the left leg and the left ear; †MIC = 1 mg/L; MIC ≤1 mg/L is considered to be susceptible (1); ‡Based on Food and Drug Administration interpretive criteria. I Intermediate; R Resistant; S Sensitive

dosing to a continuous infusion. Ciprofloxacin was added to the treatment regimen based on the susceptibility pattern of the *P. aeruginosa* isolate (Table 1, isolate D). Given the broad-spectrum antibiotics and severe burns, the patient was also given fluconazole prophylaxis.

On day 7 postadmission, the patient's skin grafts were noted to be necrotic in an area of previously exposed tarsal bone. She was taken to the operating room to investigate a potential osteomyelitis. Purulent material adjacent to the first metatarsal bone of the right foot was submitted to the laboratory, and ultimately yielded *P. aeruginosa* and *Providencia stuartii* on culture (isolates E and F; Table 1). This new *P. aeruginosa* isolate exhibited a different susceptibility pattern compared with the previously isolated *P. aeruginosa*, and was susceptible to amikacin and tobramycin but resistant to meropenem (Table 1). Therefore, amikacin was added to the patient's treatment regimen. Given the presumptively infected bone, the patient completed six weeks of combined antimicrobial therapy (vancomycin, continuous infusion meropenem, ciprofloxacin and amikacin) for osteomyelitis. She improved rapidly following the addition of amikacin and was discharged home with no further complications.

The MDR *K. pneumoniae* (isolate C) and *P. aeruginosa* (isolate D) isolates were forwarded to the National Microbiology Laboratory in Winnipeg, Manitoba, for further evaluation. Two multiplex polymerase chain reactions (PCRs), one for the detection of beta-lactamase genes (SHV, TEM, CTX-M, OXA-1 and CMY-2) and one for the detection of carbapenemase genes (KPC, NDM, IMP, VIM, GES and OXA-48) were used as previously described (3,4). The *K. pneumoniae* isolate (isolate C) was positive for SHV, TEM, CTX-M, OXA-1 and OXA-48, and was considered to be an extended-spectrum

beta-lactamase (ESBL) producer and molecular class D OXA-48 carbapenemase producer. The *P. aeruginosa* isolate (isolate D) was positive for GES by PCR and sequencing confirmed that it possessed GES-13, a molecular class A carbapenemase. The carbapenemase PCR was also performed on the *P. stuartii* isolate (isolate F) and the second isolate of *P. aeruginosa* (isolate E); these were both negative.

DISCUSSION

Carbapenemases are beta-lactamase enzymes capable of hydrolyzing carbapenem antimicrobials (5). While some bacteria intrinsically produce a carbapenemase, *P. aeruginosa* and many members of the family *Enterobacteriaceae* acquire carbapenemases through mobile genetic elements such as plasmids (3). The global dissemination of carbapenemase-producing bacteria is of great concern because these organisms are often MDR, leaving clinicians with few therapeutic options from which to choose (5).

GES beta-lactamases (GES-1 to GES-23; www.lahey.org) are a group of molecular class A enzymes with extended-spectrum properties (6). GES-13 differs from GES-1 by the presence of Glu104→Lys and Gly170→Asn. The presence of Lys-104 has been associated with increased activity against oxyimino-beta-lactams, mainly ceftazidime and aztreonam, whereas Asn-170 lends the enzyme weak carbapenemase activity (6). GES-13 was first isolated in a MDR strain of *P. aeruginosa* from a patient with a respiratory infection in Athens, Greece (7). Laboratory detection of GES enzymes in *P. aeruginosa* relies on molecular methods because a specific phenotypic test does not exist. In the case described here, the decision to investigate for possible carbapenemase production was made based on the patient's travel

history. To our knowledge, the present report describes the first case of a GES-13-producing organism identified in Canada.

OXA-type carbapenemases are molecular class D enzymes that have been primarily associated with *Acinetobacter baumannii* (8). In 2001, the first case of an OXA-48-producing *K pneumoniae* was reported from Istanbul, Turkey (9,10). For several years, OXA-48 was identified only in patients hospitalized in Turkey or with some link to this country (9,10). However, more recently, the plasmid-mediated OXA-48 and related variants have been detected in *Enterobacteriaceae* from the Middle East, North Africa, India, Europe and North America (4,9,11,12). Although OXA-48 displays weak activity against carbapenems and extended-spectrum cephalosporins, isolates harbouring this enzyme often produce other ESBLs (4,9,12). Identification of OXA-48-producing *Enterobacteriaceae* in the clinical laboratory setting is challenging due to the lack of a specific phenotypic test (10,13). Furthermore, these isolates may test susceptible to carbapenems, albeit with relatively elevated MICs. In a recent study by Potron et al (9), 68.6% and 69.5% of 105 OXA-48-producing *Enterobacteriaceae* were susceptible to imipenem and meropenem, respectively, according to current CLSI breakpoints. Poirel et al (10) have proposed that carbapenemase production among *Enterobacteriaceae* be suspected for isolates with an ertapenem MIC ≥ 0.5 mg/L, or an imipenem or meropenem MIC ≥ 1 mg/L. Molecular-based techniques (PCR) remain the gold standard for detection of OXA-48 among *Enterobacteriaceae* (10,14). In our case, the OXA-48-producing *K pneumoniae* isolate was resistant to ertapenem (MIC 4 mg/L) and had a relatively elevated meropenem MIC of 1 mg/L (Table 1). On molecular testing, this isolate was positive for SHV, TEM, CTX-M, OXA-1 and OXA-48 by PCR. The CTX-M enzyme was likely responsible for the extended-spectrum cephalosporin resistance demonstrated by the isolate, as has been previously reported (4,9,12).

The present case highlights several of the challenges associated with MDR organisms. As the frequency of worldwide travel continues to increase, clinicians will need to be aware of not only local epidemiology but also global trends in antimicrobial resistance. Treatment of

infections caused by MDR organisms may require complicated and potentially toxic antimicrobial combinations. The regimen used in the present case resulted in excellent clinical response but required a prolonged hospital stay for the medications to be effectively delivered. The extended use of an aminoglycoside was well tolerated in our pediatric patient; however, nephrotoxicity from aminoglycosides may be a greater concern in older age groups and/or patients with underlying renal impairment.

Evidence for the use of continuous beta-lactam infusions is limited, particularly in the pediatric population (15-17). Given the *K pneumoniae* carbapenem MIC of 1 mg/L found in our patient, combined with abnormal blood flow in a burn setting with infected bone, it was the option pursued due to concern over achieving sufficient drug levels in the targeted tissues. While the need for multiple antibiotics made drawing specific conclusions about the role of the continuous infusion difficult, the clinical success of the approach was notable.

SUMMARY

We report the first case of a GES-13 carbapenemase-producing *P aeruginosa* in Canada, recovered from the wounds of an infant who sustained burns while travelling in Pakistan. Also recovered from the patient's wounds were two isolates of MRSA, an MDR isolate of *P. stuartii*, and an OXA-48 carbapenemase and CTX-M ESBL-producing *K pneumoniae*. This case highlights the importance of international travel as a risk factor for infection with carbapenemase-producing bacteria. The travel history here prompted testing for carbapenemase production in the *P. aeruginosa* isolate (isolate D). Without this history, it is likely that molecular testing would not have been performed and the GES-13 enzyme would have gone undetected. This case also illustrates the difficulty faced by clinical microbiology laboratories in detecting OXA-48-producing *Enterobacteriaceae* because many of these isolates remain susceptible to imipenem and meropenem based on current CLSI breakpoints. Molecular testing remains the gold standard for detection of carbapenemase enzymes among *Enterobacteriaceae*.

REFERENCES

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. M100-S23. Wayne: Clinical and Laboratory Standards Institute, 2013.
2. Mulvey MR, Chui L, Ismail J, et al. Development of a Canadian standardized protocol for subtyping methicillin-resistant *Staphylococcus aureus* using pulsed-field gel electrophoresis. *J Clin Microbiol* 2001;39:3481-5.
3. Mataseje LF, Bryce E, Roscoe D, et al. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: Results from the Canadian Nosocomial Infection Surveillance Program (CNISP). *J Antimicrob Chemother* 2012;67:1359-67.
4. Mataseje LF, Boyd DA, Hoang L, et al. Carbapenem-hydrolyzing oxacillinase-48 and oxacillinase-181 in Canada, 2011. *Emerg Infect Dis* 2013;19:157-60.
5. Cornaglia G, Rossolini GM. The emerging threat of acquired carbapenemases in Gram-negative bacteria. *Clin Microbiol Infect* 2010;16:99-101.
6. Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS. Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β -lactamases. *Antimicrob Agents Chemother* 2010;54:4864-71.
7. Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS. GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010;54:1331-3.
8. Walther-Rasmussen J, Høiby N. Oxa-type carbapenemases. *J Antimicrob Chemother* 2006;57:373-83.
9. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 beta-lactamase-producing *Enterobacteriaceae* over a 11-year period, 2001 to 2011. *Euro Surveill* 2013;18: pii=20549.
10. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: The phantom menace. *J Antimicrob Chemother* 2012;67:1597-606.
11. Kilic A, Aktas Z, Bedir O, et al. Identification and characterization of OXA-48 producing, carbapenem-resistant *Enterobacteriaceae* isolates in Turkey. *Ann Clin Lab Sci* 2011;41:161-6.
12. Mathers AJ, Hazen KC, Carroll J, et al. First clinical cases of OXA-48-producing carbapenem-resistant *Klebsiella pneumoniae* in the United States: the "menace" arrives in the new world. *J Clin Microbiol* 2013;51:680-3. (Erratum in 2013;51:1352).
13. Nordmann P, Gniadkowski M, Giske CG, et al. Identification and screening of carbapenemase-producing *Enterobacteriaceae*. *Clin Microbiol Infect* 2012;18:432-8.
14. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of *Enterobacteriaceae* that produce carbapenemases. *J Clin Microbiol* 2012;50:3877-80.
15. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis. *Clin Infect Dis* 2013;56:272-82.
16. Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant *Pseudomonas aeruginosa* infections in immunocompromised patients. *Ann Pharmacother* 2010;44:929-35.
17. Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of β -lactam antibiotics in the pediatric population. *Ann Pharmacother* 2012;46:1537-46.